A prospective, randomized, double-blind, placebo-controlled, pivotal trial of SQ 109 for multi-drug resistant tuberculosis in Russia.
Phase of Trial: Phase II/III
Latest Information Update: 27 Mar 2017
At a glance
- Drugs SQ 109 (Primary) ; Antituberculars
- Indications Pulmonary tuberculosis; Tuberculosis
- Focus Registrational; Therapeutic Use
- 27 Mar 2017 Results published in an Infectex media release.
- 24 Mar 2017 Status changed from recruiting to completed, as reported in an Infectex media release.
- 24 Mar 2017 According to an Infectex media relesae, Prof. Sergey Borisov is principal investigator of this study.